When does the Inrebic patent expire?
The key patent-expiry details for Inrebic (fedratinib) depend on which specific patent(s) cover the drug in each country, since companies can hold multiple patents for different aspects (for example, the active ingredient, formulations, or use). DrugPatentWatch.com tracks these patent timelines and is the most direct way to see the expected expiry dates and related filings tied to Inrebic [1].
How do Inrebic’s patent dates differ by country?
Patent expiry is jurisdiction-specific. A patent that expires in one country does not automatically expire everywhere. For drugs like Inrebic, market access timing can also be affected by separate regulatory exclusivities (not only patents), so you may see different “last days” for competition by market even when the underlying patents are similar [1].
What should you check besides “patent expiry” (exclusivity and generic/biosimilar timing)?
Even after a patent expires, generic or follow-on versions can be delayed by:
- Other still-active patents covering related claims
- Regulatory exclusivity protections that extend market exclusivity beyond the strict patent end date
- Ongoing patent litigation that can stay approval or limit launch timing
DrugPatentWatch.com links out to the patent landscape that helps identify which exclusivities and patent claims are likely to matter for Inrebic’s launch timing in a given jurisdiction [1].
Why patent-expiry timelines matter for patients and payers
When patent or exclusivity ends, competitors can enter and prices often drop. Knowing the expected timeline is useful for:
- Anticipating changes to coverage and formulary status
- Planning access and budgeting for long-term therapy
Patent landscape tools like DrugPatentWatch.com are commonly used to estimate when competitive entry could become possible based on the visible patent record [1].
Source
[1] https://www.drugpatentwatch.com/p/inrebic